scholarly journals Evaluation of Dosimetric Properties of Handmade Bolus for Megavoltage Electron and Photon Radiation Therapy

Author(s):  
Endarko Endarko
2012 ◽  
Vol 82 (1) ◽  
pp. 242-249 ◽  
Author(s):  
Charles B. Simone ◽  
Kevin Kramer ◽  
William P. O’Meara ◽  
Justin E. Bekelman ◽  
Arnaud Belard ◽  
...  

2019 ◽  
Vol 15 (1) ◽  
Author(s):  
Michael A. Deveau ◽  
Megan Sutton ◽  
Courtney Baetge ◽  
Alison B. Diesel

Abstract Background Total skin electron beam radiation therapy (TSEBT) is an effective treatment for primary diffuse cutaneous lymphomas in humans. While several techniques exist, they all require significant commitment of staff time and resources. In veterinary medicine, canine-specific techniques and strategies have been adapted and delivered but deemed not “realistically” clinically implementable given the time commitment of over 2.5 h plus per fraction or have been relegated to palliative intent. Leveraging these technologies of helical tomotherapy and 3D printing, we developed and clinically implemented a radiotherapeutic treatment strategy for the management of medically refractory diffuse cutaneous lymphoma in the dog. Case presentation A 13.5-year-old female spayed Bichon Frise presented to the Oncology service at Texas A&M University, College of Veterinary Medicine due to the progression of diffuse cutaneous epitheliotropic lymphoma (CEL) that had failed medical management. Twenty-seven gray were delivered to the patient with a treatment time requirement under 40 min including real time monitoring of anesthesia during setup and treatment. A partial response was noticeable after four fractions and the tumor completely regressed progressively over the entire treated area by the end of therapy. A grade 1 lethargy, fatigue, weight loss, and oral mucositis and grade 2 alopecia, nail/claw changes, pruritus, scaling, anorexia, and diarrhea were noted during treatment. Additionally, a grade 3 thrombocytopenia developed after fraction eight requiring a treatment interruption of 6 weeks and prescription modification prior to treatment continuation and completion. From the beginning of total skin photon radiation therapy (TSPT) treatment until the time of the patient was euthanized unrelated to cutaneous epitheliotropic lymphoma (123 days), only one new lesion on the head was identified and confirmed by histopathology within the treated fields. Conclusions The proposed technique is an acceptable alternative to TSEBT that is actually clinically implementable within a palliative or definitive setting and clinical constraints, however further testing and refinement is needed to reduce hematological complications and to confirm and expand on preliminary findings.


2019 ◽  
Vol 20 (17) ◽  
pp. 4148 ◽  
Author(s):  
Toshiaki Matsui ◽  
Endang Nuryadi ◽  
Shuichiro Komatsu ◽  
Yuka Hirota ◽  
Atsushi Shibata ◽  
...  

Photon radiation therapy is a major curative treatment for cancer. However, the lack of robust predictive biomarkers for radiosensitivity precludes personalized radiation therapy. Clonogenic assays are the gold standard method for measuring the radiosensitivity of cancer cells. Although a large number of publications describe the use of clonogenic assays to measure cancer cell radiosensitivity, the robustness of results from different studies is unclear. To address this, we conducted a comprehensive detailed literature search of 256 common cancer cell lines and identified the eight cell lines most-frequently examined for photon sensitivity using clonogenic assays. Survival endpoints and experimental parameters from all 620 relevant experiments were compiled and analyzed. We found that the coefficients of variation for SF2 (surviving fraction after 2 Gy irradiation) and for D10 (dose that yields a surviving fraction of 10%) were below 30% for all cell lines, indicating that SF2 and D10 have acceptable inter-assay precision. These data support further analysis of published data on clonogenic assays using SF2 and D10 as survival endpoints, which facilitates robust identification of biological profiles representative of cancer cell sensitivity to photons.


Author(s):  
A.J. Bishop ◽  
K.T. Tran ◽  
P.K. Allen ◽  
A. Mahajan ◽  
M.F. McAleer ◽  
...  

Author(s):  
D.M. Routman ◽  
A. Garant ◽  
S.C. Lester ◽  
C.N. Day ◽  
C.T. Sanhueza ◽  
...  

Author(s):  
Markus Fitzek ◽  
Allan Thornton ◽  
James Rabenow ◽  
Michael Lev ◽  
Francisco Pardo ◽  
...  

Author(s):  
А. Самойлов ◽  
A. Samoylov ◽  
Ж. Смирнова ◽  
Zh. Smirnova ◽  
В. Климанов ◽  
...  

This paper analyzes the current state of clinical application of proton radiation therapy (PRT) for the treatment of cancer. In particular, the indications for the use of PRT for the treatment of specific pathologies, the results and condition of randomized clinical studies of PRT compared to photon radiation therapy (PhRT) are considered, the cost of PRT is compared with the cost of PhRT. The focus is on discussing the results of PRT using in advanced countriesand Russia for the treatment of several common tumor sites. In the conclusion of the work, the ways of further improvement of radiobiology, dose delivering technology and dosimetric support of PRT are considered.


2019 ◽  
Vol 37 (4_suppl) ◽  
pp. 412-412 ◽  
Author(s):  
Alicia Smart ◽  
Theodore S. Hong ◽  
Natasa Petkovska ◽  
Bridget N. Noe ◽  
Andrew X. Zhu ◽  
...  

412 Background: Our objective was to evaluate outcomes for patients with unresectable/locally recurrent intrahepatic cholangiocarcinoma (ICC) treated with hypofractionated proton or photon radiation therapy (HF-RT). Methods: We retrospectively identified 66 patients with ICC who were treated with HF-RT from 2008-18. 51 patients had intrahepatic disease only, and 15 patients had extrahepatic disease at time of RT but received RT for biliary control. Median age at RT was 76 years (range: 30-92), including 27 patients (41%) ≥ 80 years. Median RT dose was 58.05 Gy (range: 37.5-67.5), delivered in 15 daily fractions. 32 patients received proton RT, and 34 patients received photon RT. Rates of local control (LC), progression-free survival (PFS), and overall survival (OS) were calculated by the Kaplan-Meier method. Univariate and multivariate analyses were conducted using the Cox proportional hazards method. For multivariate analyses, variables with p < 0.5 on univariate analysis were evaluated by backwards selection. Results: Median follow-up times from diagnosis and RT start were 21 and 14 months, respectively. In total, 5 patients (7.6%) developed local failure. Only 1 patient developed isolated local failure. The 2-yr outcomes were 93% LC, 37% PFS, and 55% OS. Among the 51 patients treated with definitive intent, the 2-yr LC was 96%, PFS 35%, OS 60%. Receipt of protons was significantly associated with younger age (p = 0.02), but not gender, race, ECOG status, metastatic disease at presentation, mean liver dose, cumulative GTV, or number of lesions. There were no significant predictors of LC or PFS, including RT dose. On UVA for OS, younger age, female gender, prior chemotherapy, prior surgery, and proton RT were associated with improved OS (p < 0.05). On MVA, female gender (HR: 0.33, p = 0.001), prior chemotherapy (HR: 0.38, p = 0.002), and proton vs. photon RT (HR: 0.50, p = 0.05) remained significantly associated with OS. Conclusions: HF-RT yields high rates of local control and is an effective modality to optimize biliary control for unresectable/locally recurrent IC. HF-RT should be considered for elderly patients who are considered medically inoperable. Proton RT and chemotherapy may further improve outcomes.


2003 ◽  
Vol 48 (16) ◽  
pp. 2617-2631 ◽  
Author(s):  
D Schulz-Ertner ◽  
A Nikoghosyan ◽  
B Didinger ◽  
C P Karger ◽  
O J kel ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document